中等度から重度の活動性クローン病（CD）の成人患者における疾患活動性および有害事象の変化を評価する観察研究

基本情報

NCT ID

NCT05841537

ステータス

実施中（募集終了）

試験のフェーズ

-

試験タイプ

観察

目標被験者数

1,019

治験依頼者名

AbbVie

概要

Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective risankizumab is in treating moderately to severely active CD in real world. Adverse events and change in disease activity will be assessed. Risankizumab is a drug approved for the treatment of CD. All study participants will receive risankizumab as prescribed by their study doctor in accordance with approved local label. Approximately 1000 participants will be enrolled worldwide. Participants will receive risankizumab as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 36 months. There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site or virtually as per standard of care.

対象疾患

依頼者（Sponsor）

実施施設 (24)